Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) – Research analysts at Wedbush raised their FY2026 earnings per share (EPS) estimates for Fate Therapeutics in a report issued on Thursday, August 4th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of $0.66 per share for the year, up from their prior estimate of $0.65. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($3.37) per share.
Fate Therapeutics (NASDAQ:FATE – Get Rating) last announced its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.10. The business had revenue of $18.40 million during the quarter, compared to the consensus estimate of $9.01 million. Fate Therapeutics had a negative return on equity of 38.88% and a negative net margin of 371.73%. The business’s quarterly revenue was up 65.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.48) EPS.
Fate Therapeutics Price Performance
Shares of FATE stock opened at $33.42 on Friday. The company has a market cap of $3.23 billion, a price-to-earnings ratio of -12.66 and a beta of 1.62. The stock has a 50 day simple moving average of $26.91 and a 200-day simple moving average of $31.46. Fate Therapeutics has a 1-year low of $17.10 and a 1-year high of $97.43.
Insider Buying and Selling at Fate Therapeutics
In other Fate Therapeutics news, Director John Mendlein sold 1,364 shares of the company’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $22.79, for a total value of $31,085.56. Following the completion of the sale, the director now directly owns 158,091 shares in the company, valued at approximately $3,602,893.89. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director John Mendlein sold 1,364 shares of the stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $22.79, for a total transaction of $31,085.56. Following the completion of the transaction, the director now directly owns 158,091 shares in the company, valued at approximately $3,602,893.89. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mark Plavsic sold 3,719 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $24.61, for a total value of $91,524.59. Following the transaction, the insider now owns 127,123 shares of the company’s stock, valued at $3,128,497.03. The disclosure for this sale can be found here. Insiders sold a total of 53,082 shares of company stock worth $1,646,106 in the last three months. 18.58% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Fate Therapeutics
A number of hedge funds have recently modified their holdings of FATE. National Bank of Canada FI acquired a new position in Fate Therapeutics during the 2nd quarter worth about $25,000. Compagnie Lombard Odier SCmA acquired a new position in Fate Therapeutics during the 1st quarter worth about $70,000. KRS Capital Management LLC acquired a new position in Fate Therapeutics during the 4th quarter worth about $125,000. Point72 Hong Kong Ltd acquired a new position in Fate Therapeutics during the 1st quarter worth about $180,000. Finally, Virtus ETF Advisers LLC lifted its stake in Fate Therapeutics by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,274 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 918 shares in the last quarter.
About Fate Therapeutics
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
- Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.